ZyCoV-D will become the first Indian vaccine based on DNA, target of 50 million doses by Dec 2021

New Delhi: Indian pharma major Zydus Cadila has claimed that if their vaccine ZyCoV-D is approved by the regulators, it will be the world’s first DNA vaccine. The vaccine uses a portion of the genetic code of the COVID-19 virus to induce an immune response in recipients.

For this, approval for emergency use has been sought from the Drug Controller General of India (DCGI). This corona vaccine, which is being said to be safe for children, has many features. This is the first plasmid DNA vaccine. Simultaneously, it will be injected with FamaZjet technology without the help of a needle, which will reduce the risk of side effects.

Let us inform that the third phase trial of Zydus Cadila’s corona vaccine ZyCoV-D has been done. It was attended by 28 thousand participants. This is the largest trial of any vaccine in India so far, its results have also been said to be satisfactory. It was trialed at 50 clinical sites in the country only during the second corona wave. It is also said to be effective on the Delta variant.

Other vaccines such as Pfizer and ModZ are based on mRNA technology, while Covishield uses viral vector technology.

Meanwhile, Zydus Cadila MD Sharvil Patel said the company aims to produce 50 million doses by December 2021.

(with agency input)

Also read in Hindi: ZyCoV-D बनेगी DNA पर आधारित पहली भारतीय वैक्सीन, Dec 2021 तक 5 करोड़ डोज का लक्ष्य

Add a Comment

Your email address will not be published.